Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

education programme

Virtual Grant Writing & Review – Engaging Your Advisors Creatively

Boost your research initiatives! Discover how to creatively manage virtual grant writing & review programs with your KOLs, identifying key topics & streamlining proposal approvals. Foster impactful collaborations. Watch

Impetus Digital

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

Better together – accelerating innovation and access to rare disease treatments

Advancing rare disease research through global collaborations and unified clinical trials

- PMLiVE

FDA approves Nuvation Bio’s TKI inhibitor Ibtrozi to treat rare form of lung cancer

ROS1-positive non-small cell lung cancer accounts for approximately 2% of new NSCLC cases

- PMLiVE

NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

- PMLiVE

Galderma shares positive two-year results for Nemluvio in atopic dermatitis

The chronic inflammatory skin disease affects more than 230 million people worldwide

- PMLiVE

Darwin’s dictum on data

Take a view about what you see and then ask how well your view stands up against everything else you see

- PMLiVE

Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants

Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight

- PMLiVE

Alnylam’s Amvuttra granted EC approval to treat rare heart disease ATTR-CM

The RNAi therapeutic has been authorised to treat both wild type and hereditary forms of the disease

- PMLiVE

Sobi/Apellis’ pegcetacoplan shows sustained efficacy in phase 3 kidney disease study

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US and up to 8,000 in Europe

- PMLiVE

PM Society and the Chartered Institute of Marketing announce partnership

The alliance will centre around a series of face-to-face development training days in October

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links